Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H9NO4 |
Molecular Weight | 147.1293 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=WHUUTDBJXJRKMK-VKHMYHEASA-N
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
Molecular Formula | C5H9NO4 |
Molecular Weight | 147.1293 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB00142Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11724641
Sources: https://www.drugbank.ca/drugs/DB00142
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11724641
Glutamic acid is a non-essential aminoacid used in biosynthesis of proteins. Besides being a building block of proteins, glutamic acid plays a principal role in neural activation. Glutamate is also responsible for the umami (savory) flavor of certain foods. In medicine, glutamate is used as a metabolic supplemnet in patients undergoing coronary surgery.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10812962 |
|||
Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2552114 |
|||
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10812962 |
|||
Target ID: CHEMBL3772 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9131252 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. | 2001 Dec |
|
Interaction between vanilloid and glutamate receptors in the central modulation of nociception. | 2002 Mar 29 |
|
FLJ14813 missense mutation: a candidate for autosomal dominant thrombocytopenia on human chromosome 10. | 2003 |
|
GABAA receptor-expressing astrocytes in the supraoptic nucleus lack glutamate uptake and receptor currents. | 2003 Nov |
|
Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. | 2004 Apr |
|
Synthesis of chlorophyll b: localization of chlorophyllide a oxygenase and discovery of a stable radical in the catalytic subunit. | 2004 Apr 15 |
|
Spatiotemporal evidence of apoptosis-mediated ischemic injury in organotypic hippocampal slice cultures. | 2004 Jul |
|
Expression of connexin36 in cone pedicles and OFF-cone bipolar cells of the mouse retina. | 2004 Mar 31 |
|
Anesthetic-induced burst suppression EEG activity requires glutamate-mediated excitatory synaptic transmission. | 2005 Sep |
|
The drugs don't work-or do they? Pharmacological and transgenic studies of the contribution of NMDA and GluR-A-containing AMPA receptors to hippocampal-dependent memory. | 2006 Nov |
|
Inhibition of excitatory synaptic transmission by trans-resveratrol in rat hippocampus. | 2006 Sep 21 |
|
Lidocaine: neurobiological targets and effects on the auditory system. | 2007 |
|
Felbamate but not phenytoin or gabapentin reduces glutamate release by blocking presynaptic NMDA receptors in the entorhinal cortex. | 2007 Dec |
|
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. | 2007 Nov |
|
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. | 2007 Oct |
|
Rapid synapse-specific regulation of hypothalamic magnocellular neurons by glucocorticoids. | 2008 |
|
Genetics of Meesmann corneal dystrophy: a novel mutation in the keratin 3 gene in an asymptomatic family suggests genotype-phenotype correlation. | 2008 Sep 15 |
|
Phosphono analogues of 2-oxoglutarate protect cerebellar granule neurons upon glutamate excitotoxicity. | 2009 Aug |
|
Computational structural analysis and kinetic studies of a cytosolic glutamine synthetase from Camellia sinensis (L.) O. Kuntze. | 2009 Dec |
|
Biochemical evidence for the tyrosine involvement in cationic intermediate stabilization in mouse beta-carotene 15, 15'-monooxygenase. | 2009 Dec 14 |
|
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. | 2009 Dec 23 |
|
Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. | 2009 Jun |
|
Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. | 2009 May 14 |
|
Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. | 2010 Feb 10 |
|
On the structure of the proton-binding site in the F(o) rotor of chloroplast ATP synthases. | 2010 Jan 8 |
|
Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. | 2010 Jun 26 |
|
Entamoeba histolytica Phosphoserine aminotransferase (EhPSAT): insights into the structure-function relationship. | 2010 Mar 3 |
|
Cholinergic modulation of fast inhibitory and excitatory transmission to pedunculopontine thalamic projecting neurons. | 2010 May |
|
Molecular and cellular mechanisms of excitotoxic neuronal death. | 2010 Nov |
|
Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. | 2010 Nov 26 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11724641
As a dietary supplement for taste improvement, glutamate is administered orally with food. Glutamate is administered intravenously in patients undergoing coronary artery bypass surgery.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2552114
To study binding of glutamate to AMPA and Kainate ion channels, [3H]APMA and [3H]kainic acid were used as a radioligands.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 15:54:59 UTC 2022
by
admin
on
Fri Dec 16 15:54:59 UTC 2022
|
Record UNII |
3KX376GY7L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
INS-620
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-620
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
EPA PESTICIDE CODE |
374350
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
CFR |
21 CFR 310.532
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
DSLD |
2305 (Number of products:567)
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
WHO-ATC |
A09AB01
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
||
|
FDA ORPHAN DRUG |
806920
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL575060
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
SUB11991MIG
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
490
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
1294976
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
6899-05-4
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
ALTERNATIVE | |||
|
Glutamate (neurotransmitter)
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
DB00142
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
D018698
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
INS-620
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
GLUTAMIC ACID
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
33032
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
M5775
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | Merck Index | ||
|
200-293-7
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
29972
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
1310
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
16015
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
C1115
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
SUB35454
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
3KX376GY7L
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
3KX376GY7L
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
143503
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
25916
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | RxNorm | ||
|
56-86-0
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
DTXSID5020659
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
18237
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY | |||
|
66
Created by
admin on Fri Dec 16 15:54:59 UTC 2022 , Edited by admin on Fri Dec 16 15:54:59 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
The endogenous agonist
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
INHIBITOR -> TARGET |
INHIBITS GLUTAMATE RELEASE
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |